An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer

Watch this CME-certified on-demand Webcast of a CCO symposium at ASCO 2019 to get up to date on how experts are managing patients with HR+/HER2- MBC, including the optimal application of CDK4/6 inhibitors, the evolving role of PI3K pathway blockade, promising strategies on the horizon for managing resistance, and panel case discussions.
Joyce O'Shaughnessy, MD
Program Director
Adam M. Brufsky, MD, PhD
Sara Hurvitz, MD, FACP
Released: July 5, 2019 Expiration: No longer available for credit

Related Content

Watch this on-demand Webcast on the evolving use of antibody–drug conjugates in the care of patients with advanced breast cancer from Clinical Care Options (CCO)

Prof Michael Untch, MD, PhD
Program Director
Javier Cortes, MD, PhD Ian E. Krop, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 30, 2020 Expired: November 29, 2021

In this slideset from Clinical Care Options, a panel of international experts review the role of PARP inhibitors for patients with metastatic breast cancer.

person default Pierfranco Conte, MD Véronique Diéras, MD Mark E. Robson, MD Released: November 24, 2020

Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO

Heather McArthur, MD, MPH Released: November 20, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue